KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to 12.83%.

  • Acadia Pharmaceuticals' EBIT Margin rose 2000.0% to 12.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 23.01%, marking a year-over-year increase of 109300.0%. This contributed to the annual value of 24.1% for FY2024, which is 342000.0% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its EBIT Margin stood at 12.83% for Q3 2025, which was up 2000.0% from 12.24% recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year EBIT Margin high stood at 59.13% for Q4 2024, and its period low was 97.88% during Q1 2022.
  • For the 5-year period, Acadia Pharmaceuticals' EBIT Margin averaged around 13.55%, with its median value being 11.63% (2021).
  • In the last 5 years, Acadia Pharmaceuticals' EBIT Margin surged by 596100bps in 2021 and then tumbled by -352100bps in 2022.
  • Acadia Pharmaceuticals' EBIT Margin (Quarter) stood at 34.15% in 2021, then rose by 1bps to 33.75% in 2022, then skyrocketed by 145bps to 15.12% in 2023, then skyrocketed by 291bps to 59.13% in 2024, then crashed by -78bps to 12.83% in 2025.
  • Its EBIT Margin was 12.83% in Q3 2025, compared to 12.24% in Q2 2025 and 7.9% in Q1 2025.